| scholarly article | Q13442814 |
| P50 | author | Dafna D. Gladman | Q37605821 |
| P2093 | author name string | Philip J Mease | |
| Ernest H S Choy | |||
| Christopher T Ritchlin | |||
| Eric H Sasso | |||
| Renee J Perdok | |||
| John T Sharp | |||
| Peter A Ory | |||
| P433 | issue | 2 | |
| P921 | main subject | adalimumab | Q348260 |
| psoriatic arthritis | Q511097 | ||
| P304 | page(s) | 476-488 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial | |
| P478 | volume | 56 |
| Q36434813 | A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. |
| Q38840271 | A Review of Psoriasis, Therapies, and Suicide. |
| Q48738063 | Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial |
| Q37939197 | Acrodermatitis continua of Hallopeau: evolution of treatment options |
| Q31169591 | Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) |
| Q52903765 | Adalimumab for the treatment of psoriatic arthritis. |
| Q58434950 | Adalimumab for the treatment of severe psoriasis and psoriatic arthritis |
| Q37142425 | Adalimumab in dermatology |
| Q38207760 | Adalimumab in the treatment of immune-mediated diseases |
| Q37991693 | Adalimumab monotherapy in a patient with psoriatic arthritis associated with chronic renal failure on hemodialysis: a case report and literature review |
| Q37404893 | Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases |
| Q24234197 | Adverse effects of biologics: a network meta-analysis and Cochrane overview |
| Q36479450 | Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis |
| Q88646055 | Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison |
| Q38247739 | Biological agents in psoriatic arthritis |
| Q46247849 | Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? |
| Q26995307 | Clinical outcomes in psoriatic arthritis: A systematic literature review |
| Q37776265 | Combination systemic therapies in psoriatic arthritis |
| Q51289760 | Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. |
| Q34112840 | Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents |
| Q38165235 | Diagnosing and treating psoriatic arthritis: an update |
| Q38540408 | Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations |
| Q38998373 | Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis |
| Q37290478 | Drug focus: adalimumab in the treatment of moderate to severe psoriasis |
| Q37826195 | Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis |
| Q37453027 | Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. |
| Q38377748 | Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials |
| Q36182389 | Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure |
| Q38077142 | Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials |
| Q92535810 | Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study |
| Q46171462 | Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice |
| Q33566374 | Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions |
| Q44450869 | Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis |
| Q37873493 | Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
| Q51108219 | Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis. |
| Q37857668 | Emerging treatments in the management of psoriasis: biological targeting with ustekinumab |
| Q35977689 | Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study |
| Q38526206 | Gene Therapy for Cartilage Repair |
| Q46585904 | Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial |
| Q42210089 | Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. |
| Q35819025 | Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. |
| Q43695353 | Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report |
| Q47148249 | Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. |
| Q37768157 | Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies |
| Q48004654 | Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study |
| Q34620323 | Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature |
| Q26783506 | Making the next steps in psoriatic arthritis management: current status and future directions |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q27693878 | Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis |
| Q53672229 | Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. |
| Q37027264 | National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. |
| Q38634276 | Novel approaches to biological therapy for psoriatic arthritis |
| Q36182383 | Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis |
| Q90394986 | Preliminary validation of the Simplified Psoriatic Arthritis Radiographic Score (SPARS) |
| Q38630548 | Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. |
| Q45777991 | Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. |
| Q37051500 | Psoriatic arthritis: current topics |
| Q37397676 | Psoriatic arthritis: from pathogenesis to therapy |
| Q38542095 | Psoriatic arthritis: latest treatments and their place in therapy |
| Q40074154 | Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry |
| Q42534690 | Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis |
| Q81710049 | Remission in psoriatic arthritis |
| Q30399745 | Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders |
| Q34027596 | Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. |
| Q51019311 | Scintigraphy for detecting tumour necrosis factor-α on the skin of patients with psoriatic arthritis. |
| Q54978927 | Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. |
| Q90502051 | Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 |
| Q94585761 | Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial |
| Q34613907 | Spondyloarthritides: evolving therapies |
| Q40634737 | Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study |
| Q42176263 | Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study |
| Q36536861 | TNFalpha blockade in human diseases: an overview of efficacy and safety |
| Q38969036 | Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis |
| Q37303223 | Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature |
| Q38098466 | Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents |
| Q38132706 | Treatment of psoriasis and psoriatic arthritis |
| Q38204241 | Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety |
| Q39003610 | Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations. |
| Q27012134 | Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature |
| Q38264660 | Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity |
| Q41615511 | Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. |
| Q43061552 | Update in treatment options for psoriatic arthritis |
| Q84430488 | Update on the treatment of peripheral arthritis in psoriatic arthritis |
| Q36171750 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |
| Q38177336 | Ustekinumab for the treatment of psoriatic arthritis |
| Q30760660 | Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla |
| Q42783164 | Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose |
| Q52851716 | [Systemic treatments for psoriasis and psoriatic arthritis]. |
Search more.